These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
903 related items for PubMed ID: 17999839
1. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Facey K, Bradbury I, Laking G, Payne E. Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839 [Abstract] [Full Text] [Related]
2. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, Glanville J, McIntosh H, Renehan A, Weller D, Dunlop M. Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472 [Abstract] [Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Sep; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
4. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation. Cooper KL, Meng Y, Harnan S, Ward SE, Fitzgerald P, Papaioannou D, Wyld L, Ingram C, Wilkinson ID, Lorenz E. Health Technol Assess; 2011 Jan; 15(4):iii-iv, 1-134. PubMed ID: 21276372 [Abstract] [Full Text] [Related]
5. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling. Meads C, Auguste P, Davenport C, Małysiak S, Sundar S, Kowalska M, Zapalska A, Guest P, Thangaratinam S, Martin-Hirsch P, Borowiack E, Barton P, Roberts T, Khan K. Health Technol Assess; 2013 Mar; 17(12):1-323. PubMed ID: 23537558 [Abstract] [Full Text] [Related]
6. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? Langer A. BMC Health Serv Res; 2010 Oct 08; 10():283. PubMed ID: 20932288 [Abstract] [Full Text] [Related]
7. Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling. Gilbert FJ, Harris S, Miles KA, Weir-McCall JR, Qureshi NR, Rintoul RC, Dizdarevic S, Pike L, Sinclair D, Shah A, Eaton R, Clegg A, Benedetto V, Hill JE, Cook A, Tzelis D, Vale L, Brindle L, Madden J, Cozens K, Little LA, Eichhorst K, Moate P, McClement C, Peebles C, Banerjee A, Han S, Poon FW, Groves AM, Kurban L, Frew AJ, Callister ME, Crosbie P, Gleeson FV, Karunasaagarar K, Kankam O, George S. Health Technol Assess; 2022 Mar 08; 26(17):1-180. PubMed ID: 35289267 [Abstract] [Full Text] [Related]
8. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Reske SN, Kotzerke J. Eur J Nucl Med; 2001 Nov 08; 28(11):1707-23. PubMed ID: 11702115 [Abstract] [Full Text] [Related]
9. Detection of distant interval metastases after neoadjuvant therapy for esophageal cancer with 18F-FDG PET(/CT): a systematic review and meta-analysis. Kroese TE, Goense L, van Hillegersberg R, de Keizer B, Mook S, Ruurda JP, van Rossum PSN. Dis Esophagus; 2018 Dec 01; 31(12):. PubMed ID: 29917073 [Abstract] [Full Text] [Related]
10. Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Kleis M, Daldrup-Link H, Matthay K, Goldsby R, Lu Y, Schuster T, Schreck C, Chu PW, Hawkins RA, Franc BL. Eur J Nucl Med Mol Imaging; 2009 Jan 01; 36(1):23-36. PubMed ID: 18719909 [Abstract] [Full Text] [Related]
11. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, Kondo T, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H. BMC Cancer; 2008 Jun 09; 8():165. PubMed ID: 18541009 [Abstract] [Full Text] [Related]
12. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, Andronis L, Arvanitis T, Deeks J, Hyde C. Health Technol Assess; 2010 Oct 09; 14(50):1-103. PubMed ID: 21044553 [Abstract] [Full Text] [Related]
13. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ, Hutchins G, Love C, Wenck S, Daggy J. Cancer; 2005 Aug 01; 104(3):570-9. PubMed ID: 15977211 [Abstract] [Full Text] [Related]
14. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K. Interact Cardiovasc Thorac Surg; 2010 Jun 01; 10(6):1009-14. PubMed ID: 20197344 [Abstract] [Full Text] [Related]
15. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Ghaneh P, Hanson R, Titman A, Lancaster G, Plumpton C, Lloyd-Williams H, Yeo ST, Edwards RT, Johnson C, Abu Hilal M, Higginson AP, Armstrong T, Smith A, Scarsbrook A, McKay C, Carter R, Sutcliffe RP, Bramhall S, Kocher HM, Cunningham D, Pereira SP, Davidson B, Chang D, Khan S, Zealley I, Sarker D, Al Sarireh B, Charnley R, Lobo D, Nicolson M, Halloran C, Raraty M, Sutton R, Vinjamuri S, Evans J, Campbell F, Deeks J, Sanghera B, Wong WL, Neoptolemos JP. Health Technol Assess; 2018 Feb 01; 22(7):1-114. PubMed ID: 29402376 [Abstract] [Full Text] [Related]
17. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ. Chest; 2004 Apr 01; 125(4):1413-23. PubMed ID: 15078754 [Abstract] [Full Text] [Related]
18. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Auguste P, Barton P, Hyde C, Roberts TE. Health Technol Assess; 2011 Apr 01; 15(18):iii-iv, 1-54. PubMed ID: 21524363 [Abstract] [Full Text] [Related]
19. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. Bastiaannet E, Uyl-de Groot CA, Brouwers AH, van der Jagt EJ, Hoekstra OS, Oyen W, Verzijlbergen F, van Ooijen B, Thompson JF, Hoekstra HJ. Ann Surg; 2012 Apr 01; 255(4):771-6. PubMed ID: 22367443 [Abstract] [Full Text] [Related]
20. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, de Klerk JM, Oyen WJ, Meijer S, Hoekstra HJ. J Clin Oncol; 2009 Oct 01; 27(28):4774-80. PubMed ID: 19720925 [Abstract] [Full Text] [Related] Page: [Next] [New Search]